Myrio Therapeutics

What Myrio Therapeutics does

Myrio Therapeutics is a privately-held Australian biotechnology company developing HLA-targeted immunotherapies for solid tumors. The company is headquartered in Blackburn North, Melbourne (Victoria, Australia), was founded in 2009 as Affinity BIO (since rebranded), and is incorporated as Myrio Therapeutics Pty Ltd. It operates through a partnership-driven business model in which it advances therapeutic candidates via collaborations with academic and clinical institutions rather than carrying assets through late-stage development alone. The company employs 25 scientists in PC2 laboratories supported by global subject matter experts.

The company's core technology is its proprietary Retained Display™ (ReD™) platform - a patent-protected antibody discovery system co-invented by founders Ben Kiefel and Matthew Beasley. ReD generates diverse human antibodies with single-residue precision against peptide-HLA (pHLA) complexes, enabling targeting of intracellular cancer proteins that constitute approximately 90% of potential cancer targets and are inaccessible to traditional antibody approaches. Antibody libraries are built to 3 × 10^11 variants on robust single-chain scaffolds compatible with both bispecific T-cell engagers and CAR-T formats. Myrio has demonstrated the ability to "break restriction" by generating antibodies that target peptides presented across multiple HLA alleles, working across HLA-A alleles and now extended into HLA-B and HLA-C. The pipeline comprises three lead programs - KRAS G12V (lung, pancreas, colon), KRAS G12D (lung, pancreas, colon), PRAME (ovarian, melanoma, pediatric), and IGFBPL1 (small cell lung, neuroblastoma) - plus the PHOX2B program for pediatric neuroblastoma, each developed in CAR-T and T-cell engager formats.

Myrio's revenue model is anchored in licensing and co-development rather than product sales. The company seeks to monetize ReD and pipeline assets through strategic partnerships, generating revenue via licensing fees, milestone payments, royalties, and equity stakes in spinouts or joint ventures for clinical development. Named collaborators are the University of Pennsylvania Perelman School of Medicine, NYU Langone Health, and Hula Therapeutics at Children's Hospital of Philadelphia. The Hula/CHOP CAR-T clinical trial starting in 2025 represents Myrio's first clinical-stage application.

Name

Myrio Therapeutics

Legal name

Myrio Therapeutics Pty Ltd

Website

https://affinity.bio

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Myrio Therapeutics is an Australian biotechnology company developing HLA-targeted immunotherapies for solid tumors. Its proprietary Retained Display (ReD) antibody discovery platform engineers CAR-T and bispecific T-cell engagers against intracellular cancer proteins presented through the HLA pathway.

Ownership category

akta.pro rank

Product category

Immuno-oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

CAR-T & TCR-T Therapies (HLAAABAC), Bispecific & Multispecific Antibodies (HLAAAAAF), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Antibody discovery platform
• Immuno-oncology therapeutics
• CAR-T cell therapy
• Bispecific T cell engagers
• Intracellular cancer targeting

Headquarters

HQ city

Blackburn

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Licensing and Co-development: Strategy to work with partners to develop therapeutics against specific targets while establishing spinouts or joint ventures to clinically develop specific assets. Revenue generated through licensing deals, co-development partnerships, and equity stakes in spinout companies.
2. Partnership Collaborations: Collaborations with leading research institutions (University of Pennsylvania, NYU Langone Health) to advance immunotherapy development, potentially generating milestone payments and royalties.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Myrio Therapeutics develops therapeutic antibody candidates for solid tumor cancers using its proprietary Retained Display™ (ReD™) antibody discovery platform, which generates high-precision pHLA-targeting human antibodies with single residue specificity. The company builds an internal pipeline of CAR-T cell therapies and bispecific T-cell engagers targeting intracellular cancer antigens (KRAS, PRAME, IGFBPL1, PHOX2B) across multiple HLA alleles, while licensing its platform and collaborating with academic and industry partners.

Product overview

Myrio Therapeutics offers a unified platform approach centered on its proprietary Retained Display™ (ReD™) antibody development platform. The ReD™ platform generates high-precision pHLA (peptide-HLA) antibodies with single residue specificity, enabling targeting of intracellular cancer proteins that are hidden from traditional approaches. The company's therapeutic pipeline spans multiple HLA alleles and formats, including CAR-T cell therapies and bispecific T cell engagers, targeting antigens such as KRAS (G12V, G12D), PRAME, IGFBPL1, and PHOX2B across various cancer indications including lung, pancreas, colon, ovarian, melanoma, and pediatric cancers. Myrio also provides human scFv antibody fragments as research reagents for collaborators developing bispecific and CAR-T therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• Retained Display™ (ReD™) Platform Proprietary high-precision pHLA antibody development platform that generates diverse human antibodies with single residue precision for targeting intracellular cancer proteins. Works across all major HLA-A alleles and has been extended to HLA-B and HLA-C alleles, enabling population-diverse cancer therapeutics. Licensable to pharmaceutical and biotechnology partners.
• KRAS (G12V) CAR-T Program CAR-T cell therapy targeting KRAS G12V neoantigen presented on HLA-A*11 allele, developed for lung, pancreas, and colon cancers.
• KRAS (G12D) T Cell Engager Program Bispecific T cell engager targeting KRAS G12D neoantigen presented on HLA-A*11 allele, developed for lung, pancreas, and colon cancers.
• PRAME CAR-T Program CAR-T cell therapy targeting PRAME antigen presented on HLA-A*02 allele, developed for ovarian and melanoma cancers.
• PRAME T Cell Engager Program Bispecific T cell engager targeting PRAME antigen presented on HLA-A*02 allele, developed for ovarian and melanoma cancers.
• IGFBPL1 CAR-T Program CAR-T cell therapy targeting IGFBPL1 antigen presented on HLA-A*02 allele, developed for neuroblastoma and other pediatric cancers.
• IGFBPL1 T Cell Engager Program Bispecific T cell engager targeting IGFBPL1 antigen presented on HLA-A*02 allele, developed for small cell lung cancer.
• PHOX2B CAR-T Program CAR-T cell therapy targeting PHOX2B antigen presented on HLA-A*24 allele, developed for neuroblastoma and other pediatric cancers.
• Human scFv Antibody Fragments Human single-chain variable fragment (scFv) antibodies derived from Myrio's ReD platform, validated for use in bispecific and CAR-T formats. Libraries contain 3 × 10^11 diversity built on robust single-chain scaffolds and are provided to collaborators developing bispecific and CAR-T therapies.

Quantifiable outcome

• Covers more than single population-dominant allele (HLA-A*02:01), enabling therapeutics for underserved patients and populations across regional geographies
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• University of Pennsylvania Perelman School of MedicinecoreStrategic or Co-development Partner · 28 October 2025Research collaboration to develop next-generation T cell immunotherapies for solid tumors. Focus areas include peptide HLA binder discovery, bispecific T-cell engagers, and novel CAR architectures. Partnership aims for clinical development after establishing a company and securing seed funding.
• NYU Langone HealthcoreStrategic or Co-development Partner · 28 October 2025Joint research collaboration with University of Pennsylvania Perelman School of Medicine to accelerate development of next-generation T cell immunotherapies for solid tumors, focusing on the same areas of peptide HLA binder discovery, bispecific T-cell engagers, and novel CAR architectures.
• Hula Therapeutics at Children's Hospital of PhiladelphiaflagshipStrategic or Co-development Partner · 1 January 2025CAR-T cell therapy clinical trial collaboration starting in 2025. Myrio's HLA-targeting human antibody libraries and human scFv fragments are being used in CAR-T cell therapy development. This represents the company's first clinical trial application for its technology.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Harpoon Therapeutics: Harpoon (now part of Merck) developed TriTAC T cell engagers for solid tumors, including HPN328 and HPN217. Direct competitor in the bispecific T cell engager space for solid tumor applications.
• Adagene: Adagene's POWER platform performs AI-guided antibody discovery and engineering for cancer therapeutics, including bispecifics and TCEs. Comparable as a bispecific T-cell engager developer with proprietary antibody discovery technology.
• Cue Biopharma: Cue Biopharma develops Immuno-STAT bispecific T cell engagers that target peptide-HLA complexes, combining Myrio's two strategic axes (pHLA targeting and T cell engager format). Direct competitor in both modality and target class.
• Adaptimmune: Adaptimmune develops engineered TCR therapies for solid tumors, including MAGE-A4 (Tecelra) and KRAS-targeting programs. It is a direct competitor in the TCR/pHLA solid tumor space and overlaps with Myrio's KRAS G12V/G12D and PRAME pipeline targets.
• Immunocore: Immunocore's ImmTAC platform uses TCR-based molecules to target peptide-HLA complexes for cancer immunotherapy — the closest direct analog to Myrio's ReD platform in mechanism, target class, and clinical ambition. Tebentafusp is the first TCR therapeutic to reach approval, validating the pHLA-targeting modality.
• Neogene Therapeutics: Neogene (acquired by AstraZeneca) developed personalized TCR therapies targeting neoantigens including KRAS — overlapping directly with Myrio's KRAS G12V/G12D programs and approach to intracellular neoantigen targeting.
• Marengo Therapeutics: Marengo's STAR platform selectively expands T cell subsets against specific TCR mimetics, with programs targeting shared tumor antigens via pHLA recognition. Direct competitor in the TCR-mimetic antibody space for solid tumors.

Emerging players

• Maverick Therapeutics: Maverick (now part of Takeda) developed COBRA T cell engagers — conditional bispecifics activated by tumor-specific proteases. Overlaps with Myrio's bispecific T cell engager strategy and solid tumor focus.
• KSQ Therapeutics: KSQ uses genome-scale CRISPR screening to identify novel TCR and immuno-oncology targets, overlapping with Myrio's approach to discovering pHLA-targeting therapeutics for solid tumors.
• Altor BioScience: Altor develops TCR-mimetic antibodies (ALT-801, ALT-803) targeting pHLA complexes, an early-stage direct analog to Myrio's pHLA-targeting antibody approach for cancer immunotherapy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Myrio Therapeutics